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To highlight methodological challenges in the design and conduct of randomized trials of surgical in-
terventions and to propose strategies for addressing these challenges. This paper focuses on three broad
areas: enrollment; intervention; and assessment including implications for analysis. For each challenge
raised in the paper, we propose potential solutions. Enrollment poses challenges in maintaining inves-
tigator equipoise, managing conﬂict of interest and anticipating that patient preferences for speciﬁc
treatments may reduce enrollment. Intervention design and implementation pose challenges relating to
obsolescence, ﬁdelity of intervention delivery, and adherence and crossover. Assessment and analysis
raise questions regarding blinding and clustering of observations. This paper describes methodological
problems in the design and conduct of surgical randomized trials and proposes strategies for addressing
these challenges.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.This paper focuses on several methodological issues that are
especially important in the context of surgical randomized
controlled trials. This is a broad category of trials that includes
comparisons of two (or more) distinct surgical procedures (e.g.,
open vs arthroscopic); comparisons of distinct technical features
(e.g., different types of implants or screws); comparisons of surgical
vs nonoperative treatments for a given condition (e.g., arthroscopy
vs physical therapy) and still others. The authors include two
clinician investigators (a rheumatologist and an orthopedic sur-
geon) and a biostatistician. Each of us has experience in the design
and conduct of surgical trials. We planned the content of this paper
via email conversations and resolved any differences in opinion
through iterative comments on working drafts, emails and occa-
sional face to face discussions. We focus our recommendations
around three broad aspects of surgical randomized trials:o: J.N. Katz, Orthopedic and
Women's Hospital, 75 Francis
ternational. Published by Elsevier Lenrollment; intervention; and assessment including implications
for analysis.Enrollment
This section focuses on three related issues: investigator equi-
poise; conﬂict of interest; and patient preference.Investigator equipoise
As the term suggests, ‘equipoise’ refers to indifference (or equal
position) between two alternatives. In the context of an RCT,
equipoise refers to acceptance by members of the research team
that each of the arms under study offers a reasonable treatment1e3.
This is especially important for research team members engaged in
enrolling patients. If the enrolling investigator believes that one of
the treatments under study is superior, he or she may subtly steer
eligible patients away from enrollment in the trial and toward that
treatment4,5. There is no straightforward way to estimate and
remedy biases in enrollment that may arise because investigators
lack equipoise6,7.td. All rights reserved.
Table I
Challenges arising in surgical randomized trials and suggested approaches
Challenge Description Potential approaches
Investigator equipoise Surgeon investigator may believe one treatment is superior,
leading to selective enrollment and potential bias.
- Standardized enrollment scripts delivered by research staff, not the
treating surgeon.
- Screen potential surgical investigators carefully
- Role-playing to help investigators present the trial in an unbiased
fashion.
- Monitoring to detect biased enrollment.
Patient preference Patients must assess their preferences for surgical vs
nonoperative therapy to ascertain whether they are indifferent
to the options under study.
- Standardized enrollment script delivered by unbiased research staff.
- Media presentations (e.g., DVDs) providing unbiased, standardized
information on risks and beneﬁts in each arm.
Intervention obsolescence The interventions under study may already be obsolete by the
time the study is reported.
- Choose fundamental principles as study questions rather than very
speciﬁc technologies.
Intervention ﬁdelity The surgical intervention must be delivered in a standard
fashion, despite inherent variability in the procedure depending
on surgical ﬁndings.
- Meetings among surgical investigators prior to study launch to
establish protocol for intraoperative decision points.
- Ensure that all surgeons are experiencedwith the interventions under
study to avoid learning curve effects.
Crossover and adherence Subjects may cross over from nonoperative to surgical therapy
and may choose not to undergo the assigned surgery; these
phenomena make interpretation of the intention-to-treat
analyses challenging.
- Explain clearly to subjects and investigators that subjects should
adhere to assigned treatment at least until the ﬁrst assessment.
- Capture reasons for crossover when they occur.
- Specify secondary analyses a priori that include crossover as failures.
Blinding and controls Mounting evidence points to the potency of the surgical placebo
effect, creating a rationale for sham interventions. Sham
procedures present ethical, logistical and interpretative
challenges.
- Research funding bodies must be persuaded that sham procedures are
worth paying for, as many insurers will refuse to do so.
- Investigators should consider an additional ‘no treatment’ group to
quantify the sham effect.
- Research is needed to harness sham effects at lowest possible cost and
risk.
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from investigator equipoise. If investigators surgeons choose not to
present the trial to certain eligible patients, because they feel these
patients would beneﬁt more with one treatment than the other, the
selective enrollment can introduce bias. This is especially prob-
lematic if it turns out that particular subgroups of subjects have a
higher likelihood of successful outcome if they receive one treat-
ment than if they receive the comparator5. For example, if an
investigator selectively enrolls patients with more severe symp-
toms, and if treatment A turns out to be more efﬁcacious than
treatment B in those with more severe symptoms than it is in those
with less severe symptoms, then treatment A may have spuriously
favorable results.
Several approaches have been developed to address the need for
the research team to maintain equipoise. Perhaps the most
important is that the trial should be presented to the potential
subject by a member of the research team who is not involved in
the patient's care. While clinicians may identify potentially eligible
patients in their practices, they should refer these patients to
members of the research staff who present the trial in a stan-
dardized, neutral fashion. These presentations should follow scripts
developed by the research team to convey the treatment arms
neutrally. Members of the research team who present the study to
patients can engage in role-playing prior to launching the trial in
order to gain comfort with presenting the treatment arms in an
unbiased fashion. Finally, as the trial progresses the research team
can assess patterns of enrollment to discern whether particular
investigators are referring selectively. The PI and team can try to
work with such investigators and, if that is not effective, can resort
to replacing the investigators with others better able to approach
enrollment with equipoise (Table I).Conﬂicts of interest
Commercial bias and conﬂict of interest are additional reasons
for the erosion of equipoise in RCTs8. Investigators who stand to
beneﬁt ﬁnancially if the treatment under study is successful may be
especially likely to steer toward the trial those patients whom theysuspect will beneﬁt from that treatment and less likely to refer to
the trial those patients who they suspect may not beneﬁt from the
treatment9e13. In these circumstances, it is particularly critical for
the trial to be presented to potential subjects by dispassionate
research staff using standardized scripts. Clinician-investigators
with a ﬁnancial interest in one of the treatments under study
should not participate as investigators in trials that assess the ef-
ﬁcacy of that treatment.Patient preference
Patients with a strong preference for one treatment typically
decline enrollment in a trial of that treatment, knowing that they
have just a 50% chance of receiving their treatment of choice
(assuming a two-arm trial). If such patients enroll in trials theymay
be less likely to adhere if they are assigned to the comparator arm14.
Thus, it is important to provide patients with detailed, compre-
hensible information on short- and long-term beneﬁts of each
treatment under study so that they can determine whether they
have a preference for one of the treatments. Several groups of in-
vestigators have used videotaped presentations of the options,
presented in a neutral fashion that highlights the beneﬁts and
drawbacks of each intervention15e19. These programs permit po-
tential subjects to learn about risks, beneﬁts and alternatives in
their own homes, providing them with an opportunity to develop
preferences that are informed by the best evidence in the ﬁeld.
Investigators should be careful not to describe the treatment arms
in a way that subtly fosters a preference for one treatment over the
other. For example, the term ‘watchful waiting’ may suggest to
patients a weak treatment, whereas the term ‘active, individualized
monitoring,’ used to describe the same regimen, may seem more
appealing.
Enrollment in surgical trials is often slower than the in-
vestigators anticipate. This observation underscores the impor-
tance of performing a pilot recruitment so that the research team
can appreciate the number of patients that will need to be
approached to yield the desired sample. Recruitment in multiple
centers adds complexity but may permit enrollment goals to be
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study question.
Interventions
This section discusses two key aspects of interventions in sur-
gical trials, obsolescence and intervention ﬁdelity.
Obsolescence
Surgery is characterized by rapid innovation and adoption of
technology20e22. This is one of the compelling reasons to perform
surgical RCTs: new procedures and devices are introduced
frequently. However, this phenomenon creates the risk that the
intervention is no longer used by the time the trial is reported. This
is a subtle problem to prevent as it is difﬁcult to see the future.
Investigators should endeavor to study interventions that are likely
to endure, or to study broad approaches (e.g., arthroscopic vs open,
surgery vs physical therapy) that remain relevant even when the
particular surgical approaches and devices have been modiﬁed or
supplanted. In an effort to avoid studying interventions that are
likely to become obsolete, some investigators may choose to study
technical details that may remain relevant for many years but are
unlikely to change practice or result in improved quality of life for
patients. As trials are resource intensive, we suggest that in-
vestigators choose questions that could change practice and/or
alter the quality of patients' lives.
Intervention ﬁdelity
Intervention ﬁdelity refers to the extent that the intervention is
delivered in an identical fashion to each subject23. This is seldom a
problem in pharmacologic trials as the active agents and the
comparators (e.g., placebos) can be taken at well-deﬁned times of
day and are given in the form of standardized tablets or capsules.
But ﬁdelity presents challenges in trials involving surgical pro-
cedures (e.g., surgery A vs surgery B or surgery vs nonoperative
therapy)24. Each patient's anatomy is slightly different, so dissec-
tion planes, extent of lavage, control of blood loss, soft tissue
modiﬁcations and many other aspects of the intervention require
real-time, individualized decisions and actions. Surgeon experience
and the learning curve phenomenon are related, important con-
cerns25. It takes time for surgeons to become accustomed to each
procedure and to different sets of equipment26.
To address these issues of intervention ﬁdelity and learning
curve, the surgical investigators should meet prior to the study
launch in order to develop consensus on the precise surgical pro-
tocol, including the decisions to be made in the face of particular
intraoperative ﬁndings. These discussions should be summarized in
a study document and the principles should be revisited periodi-
cally at investigator meetings over the course of the study. The
surgical details for each subject should be captured with a stan-
dardized data collection form. Postoperative care including reha-
bilitation protocols should be standardized similarly. If resources
permit, sharing of intraoperative DVDs may also help to detect and
remedy departures from protocol. While it may be difﬁcult to
deﬁne and measure the learning curve, nonetheless in trials that
involve novel procedures and materials (e.g., implants, in-
struments), surgeons who have minimal experience with the pro-
cedure or equipment should not be involved.
Crossover and adherence
The issue of crossover is particularly salient in trials of operative
vs nonoperative therapy. In these settings, subjects in thenonoperative arm may discuss with their physicians the option of
crossing over to surgery if nonoperative therapy has not resulted in
beneﬁt. Also, subjects in the surgical arm may elect to decline
surgery post-randomization15,27. Both of these phenomena may
make results of the intention-to-treat analysis of the trial (in which
subjects are analyzed according to the treatment they were
assigned, not the treatment they ultimately received) difﬁcult to
interpret28. If many subjects in the nonoperative group were
actually treated surgically by the time of the primary outcome
assessment, then the intention-to-treat analysis will have
surgically-treated subjects in each arm. Further, if a substantial
number of subjects randomized to receive surgery do not undergo
the procedure by the time of the outcome assessment, as occurred
in the Spine Patient Outcomes Research Trial (SPORT)15, the prob-
lem is heightened further. The question of whether an initial
strategy of surgery leads to better outcomes than an initial strategy
of nonoperative therapy can be measured incisively in the inten-
tion-to-treat analysis. But more general inferences about whether
surgery is associated with better outcomes than nonoperative
therapy are conﬂated in the intention-to-treat analysis by the
subjects who crossed over.
Given the likelihood of crossovers, all efforts should be made to
retain subjects in their assigned treatment arms, at least until the
ﬁrst outcome assessment. Investigators should state this goal spe-
ciﬁcally in enrollment scripts and in discussions with surgeon in-
vestigators at the outset. When subjects do cross over, the
investigators should ascertain the reason for crossover and assess
the patient's status with respect to the primary outcome measure
just prior to crossover. Finally, the research team should consider an
a priori secondary analysis plan that regards crossover from one
arm to another as a failure of the assigned treatment, and include
this in their study protocol16. This approach retains the intention-
to-treat principle but acknowledges that the patient who crossed
over was in fact a failure of the initially assigned treatment arm.
Cross-over from surgery to nonoperative therapy (e.g., the patient
decides post-randomization not to undergo surgery) would simi-
larly have to be considered a failure in this type of analysis,
underscoring the importance of ensuring that surgery is delivered
promptly to those randomized to the operative arm.Assessment and implications for analysis
This section discusses two important topics, blinding of subjects
and assessors and accounting for clustering.Blinding and control groups
A small number of surgical trials that compared surgery vs a
nonoperative regimen have used sham procedures to ensure
blinding29,30. In the absence of a sham, blinding the subject to the
whether they received surgery or a nonoperative intervention is
difﬁcult. A sham procedure controls for the experience of under-
going a surgical procedure, which may be potent. In fact, invasive
procedures (surgery, injections) appear to have considerably
stronger placebo effects than medications31e33. One pragmatic
drawback to sham treatment is that payers may not reimburse for it
as they would for an accepted therapy. While insurance payers
often bear the cost of treatment in research studies when the
treatments are well established, the cost of sham generally must
come from the research funds. Sham controls also raise the ques-
tion e unresolved at present e of whether it is ethical to include a
treatment designed to have no therapeutic effects. This issue per-
tains to surgical sham procedures andmore generally to placebos of
all sorts.
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challenges. The recent sham controlled trial of arthroscopic partial
meniscectomy for degenerative meniscal tear is a good example.
Both groups underwent a structured exercise program as well as
arthroscopic surgery and lavage. While both groups had arthro-
scopic surgery, only the ‘active’ group had partial meniscal resec-
tion. The arthroscope was simply withdrawn in the sham group.
Over 80% of subjects in each group reported improvement and over
90% in each group indicated they would choose the procedure
again25. Clinicians, patients and policy makers are left to ask
whether to abandon arthroscopic partial meniscectomy. We sug-
gest when a procedure appears to be no more efﬁcacious than a
sham control, patients contemplating the procedure should be
informed that it has been shown to be nomore effective than sham.
Further, policy makers and payers will need to think carefully about
whether to support procedures that are no more efﬁcacious than
sham procedures. Finally, given the power of sham surgery and of
placebo effects in general, further research is warranted that at-
tempts to harness sham or placebo effects at the lowest possible
cost and risk to patients.Clustering of observations
In a randomized controlled trial of two treatments, we are pri-
marily interested in the effect of treatment on outcome. Naturally,
other features may also affect outcomes, including (in surgical tri-
als) the surgeon. Subjects who are treated by the same clinician
may have similar outcomes and the effect of the clinician on
outcome may be independent of the intervention and of patient
characteristics. If the surgeon inﬂuences outcomes then subjects
cared for by a particular surgeon are not entirely independent, from
a statistical standpoint. This clustering effect (of subjects within
surgeons) can be handled analytically using one of several tech-
niques. For example the investigators could include a random effect
for surgeon, or use generalized estimating equations to adjust
standard errors for non-independence of patients treated by the
same surgeons. These methods account for clustering of outcomes
within clinician or center. In addition, dummy variables designating
particular surgeons or centers can also be added as explanatory
variables.Summary
Surgery may offer patients dramatic beneﬁts, but generally at
some risk of complications and at substantial cost. The cost and
quality of life consequences of withholding effective surgery may
be substantial as well. The evidence base available to assess the
efﬁcacy of surgery is limited. To address these and related problems
it is critical to evaluate outcomes of surgical interventions rigor-
ously, in randomized controlled trials. This paper highlights
distinctive methodologic problems arising in surgical trials and
offers strategies for addressing these challenges.Author contributions
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